Journal of Hepatology
Volume 50, Issue 2 , Pages 402-411 , February 2009

Ribavirin: Current role in the optimal clinical management of chronic hepatitis C

  • K. Rajender Reddy

      Affiliations

    • GI Division, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 215 662 4276; fax: +1 215 614 0925.
    • ,
  • David R. Nelson

      Affiliations

    • Division of Gastroenterology, Hepatology, and Nutrition, University of Florida College of Medicine, Gainesville, FL, USA
    • ,
  • Stefan Zeuzem

      Affiliations

    • Department of Medicine I, JW Goethe University Hospital, Frankfurt, Germany

  • Image Result

    Increased rates of SVR by prevention of relapse in patients with chronic HCV after the addition of ribavirin to 48 weeks’ treatment with pegylated interferon alfa [12].

    Increased rates of SVR by prevention of relapse in patients with chronic HCV after the addition of ribavirin to 48 weeks’ treatment with pegylated interferon alfa [12].

  • Image Result

    SVR rates in patients with genotype 1 chronic HCV in pivotal trials of peginterferon alfa plus ribavirin. (a) SVR rates following 48 weeks of peginterferon alfa-2a plus 800mg/day ribavirin [12] and 48

    SVR rates in patients with genotype 1 chronic HCV in pivotal trials of peginterferon alfa plus ribavirin. (a) SVR rates following 48 weeks of peginterferon alfa-2a plus 800mg/day ribavirin [12] and 48 weeks of peginterferon alfa-2a plus 800mg/day or standard dose ribavirin at 1000/1200mg/day [13]. (b) SVR rates following 48 weeks of peginterferon alfa-2b plus 800mg/day ribavirin [11] and 48 weeks of peginterferon alfa-2b plus ribavirin at 800mg/day or weight-based dosing at 800–1400mg/day [43].

  • Image Result
    The relationship between ribavirin dose and probability of an SVR in patients with chronic HCV treated with peginterferon alfa-2a plus ribavirin. (a) In genotype 1 patients. (b) In genotype 2/3 patien

    The relationship between ribavirin dose and probability of an SVR in patients with chronic HCV treated with peginterferon alfa-2a plus ribavirin. (a) In genotype 1 patients. (b) In genotype 2/3 patients [40].

  • Image Result
    The impact of ribavirin dose reductions on relapse rates in patients with genotype 1 chronic HCV treated with peginterferon alfa-2a plus ribavirin [14].

    The impact of ribavirin dose reductions on relapse rates in patients with genotype 1 chronic HCV treated with peginterferon alfa-2a plus ribavirin [14].

☆ The authors declared that they have a relationship with the manufacturers of ribavirin. They received funding from the manufacturers to carry out research for this manuscript. S.Z. declared that he is on the speakers bureau, does consultancy and clinical investigation for La Roche and Schering Plough. He received support for literature search and editorial assistance from La Roche. D.R.N. declared he has a relationship with the manufacturers of the drugs involved. He did not receive funding from the manufacturers to carry out this study.

PII: S0168-8278(08)00717-4

doi: 10.1016/j.jhep.2008.11.006

Journal of Hepatology
Volume 50, Issue 2 , Pages 402-411 , February 2009

Article Tools

* Image Usage & Resolution